Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 6660 · · 11 pages · English
Summary by 6ix AI
It includes information on authorized and registered share capital, as well as confirmations regarding public float sufficiency. The total authorized share capital at the end of the month is reported, along with the number of issued shares and treasury shares. The document confirms compliance with applicable listing rules and regulatory requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AIM Vaccine
- World's First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch
- AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities
- AIM's Iterative Process High-Efficiency Diploid Rabies Vaccine Completes Phase III Clinical Trials, Efficacy Significantly Higher than Existing Market Products
- AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector
- AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S.,mRNA Platform Advantages Shine Through
Follow AIM Vaccine into a list and get an email when it puts out news.
Follow AIM Vaccine